Dianthus Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Dianthus Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue6.242.836.421.480.000.000.00
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit6.242.836.421.480.000.000.00
Operating Expenses
Research & Development83.1132.8429.3812.6150.6259.2141.34
Selling, General & Administrative24.9918.166.741.9628.0923.7618.62
Operating Expenses108.1051.0036.1214.5678.7082.9759.96
Operating Income-101.86-48.17-29.71-13.09-78.70-82.97-59.96
Other Income/Expense
Interest Income17.374.761.150.000.000.002.45
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense16.90-0.15-0.05-0.03-51.180.000.00
Income
Income Before Tax-84.97-43.56-28.48-13.11-74.94-76.77-57.52
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-84.97-43.56-28.48-13.11-74.94-76.77-57.52
Net Income - Continuous Operations-84.97-43.56-28.48-13.110.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-101.45-47.82-29.68-13.09-72.96-74.93-59.09
EBIT-84.97-48.17-29.71-13.09-74.94-76.77-59.96
Depreciation & Amortization0.410.360.032.021.98-1.840.00
Earnings Per Share
Basic EPS-3.00-8.00-33.00-1.00-27.00--3.00
Diluted EPS-3.00-8.00-33.00-1.00-27.00-33.00-3.00
Basic Shares Outstanding33.315.150.8714.822.752.3118.39
Diluted Shares Outstanding33.315.150.8714.822.752.3118.39